Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Secukinumab: First Global Approval
Mark Sanford, Kate McKeage
Drugs (2015) Vol. 75, Iss. 3, pp. 329-338
Closed Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

IL-17 Signaling: The Yin and the Yang
Nilesh Amatya, Abhishek V. Garg, Sarah L. Gaffen
Trends in Immunology (2017) Vol. 38, Iss. 5, pp. 310-322
Open Access | Times Cited: 643
Interleukin-17 and innate immunity in infections and chronic inflammation
Natasa Isailovic, Kenji Daigo, Alberto Mantovani, et al.
Journal of Autoimmunity (2015) Vol. 60, pp. 1-11
Closed Access | Times Cited: 346
Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications
Leticia Monin, Sarah L. Gaffen
Cold Spring Harbor Perspectives in Biology (2017) Vol. 10, Iss. 4, pp. a028522-a028522
Open Access | Times Cited: 295
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
Kristian Reich, Melinda Gooderham, Diamant Thaçi, et al.
The Lancet (2019) Vol. 394, Iss. 10198, pp. 576-586
Closed Access | Times Cited: 250
Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
Marie‐Astrid Boutet, Alessandra Nerviani, Gabriele Gallo Afflitto, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 2, pp. 530-530
Open Access | Times Cited: 182
Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52‐week analysis from phase III open‐label multicenter Japanese study
Shinichi Imafuku, Masaru Honma, Yukari Okubo, et al.
The Journal of Dermatology (2016) Vol. 43, Iss. 9, pp. 1011-1017
Open Access | Times Cited: 177
Interleukin-17 in Chronic Inflammatory Neurological Diseases
Jelena Milovanović, Aleksandar Arsenijević, Bojana Stojanović, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 169
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*
Richard B. Warren, Andrew Blauvelt, Yves Poulin, et al.
British Journal of Dermatology (2020) Vol. 184, Iss. 1, pp. 50-59
Open Access | Times Cited: 159
Interleukin-17: A Pleiotropic Cytokine Implicated in Inflammatory, Infectious, and Malignant Disorders
Anna Saran, Daisuke Nishizaki, Scott M. Lippman, et al.
Cytokine & Growth Factor Reviews (2025)
Open Access | Times Cited: 3
IL-17 Receptor Signaling in Oral Epithelial Cells Is Critical for Protection against Oropharyngeal Candidiasis
Heather R. Conti, Vincent M. Bruno, Erin E. Childs, et al.
Cell Host & Microbe (2016) Vol. 20, Iss. 5, pp. 606-617
Open Access | Times Cited: 162
Candida albicans–epithelial interactions and induction of mucosal innate immunity
Julian R. Naglik, Annika König, Bernhard Hube, et al.
Current Opinion in Microbiology (2017) Vol. 40, pp. 104-112
Open Access | Times Cited: 134
IL-17 in the immunopathogenesis of spondyloarthritis
Leonie S. Taams, Kathryn J. A. Steel, Ushani Srenathan, et al.
Nature Reviews Rheumatology (2018) Vol. 14, Iss. 8, pp. 453-466
Open Access | Times Cited: 127
Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation
J Li, Jean‐Laurent Casanova, Anne Puel
Mucosal Immunology (2017) Vol. 11, Iss. 3, pp. 581-589
Open Access | Times Cited: 121
IκBζ is a key driver in the development of psoriasis
Claus Johansen, Maike Mose, Pernille Ommen, et al.
Proceedings of the National Academy of Sciences (2015) Vol. 112, Iss. 43
Open Access | Times Cited: 107
Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain
J. Notario, Gustavo Deza, Eva Vilarrasa, et al.
Journal of Dermatological Treatment (2018) Vol. 30, Iss. 5, pp. 424-429
Closed Access | Times Cited: 70
MCPIP1/Regnase-1 Restricts IL-17A– and IL-17C–Dependent Skin Inflammation
Leticia Monin, Jóhann E. Guðjónsson, Erin E. Childs, et al.
The Journal of Immunology (2016) Vol. 198, Iss. 2, pp. 767-775
Open Access | Times Cited: 68
Real‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies
Matthias Augustin, D. Jullien, A. Martin, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 6, pp. 1174-1185
Open Access | Times Cited: 64
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation
Marco Galluzzo, Mark S. Talamonti, Clara De Simone, et al.
Expert Opinion on Biological Therapy (2018) Vol. 18, Iss. 7, pp. 727-735
Open Access | Times Cited: 62
Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis
Natasha Whibley, Elaine Tritto, Elisabetta Traggiai, et al.
Journal of Leukocyte Biology (2016) Vol. 99, Iss. 6, pp. 1153-1164
Open Access | Times Cited: 61
Global trends and research status in ankylosing spondylitis clinical trials: a bibliometric analysis of the last 20 years
Wenhui Zhang, Meng Li, Xuhao Li, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 7
Gut-Busters: IL-17 Ain’t Afraid of No IL-23
Natasha Whibley, Sarah L. Gaffen
Immunity (2015) Vol. 43, Iss. 4, pp. 620-622
Open Access | Times Cited: 59
Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
Theresa N. Canavan, Craig A. Elmets, Wendy Cantrell, et al.
American Journal of Clinical Dermatology (2015) Vol. 17, Iss. 1, pp. 33-47
Closed Access | Times Cited: 59
Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study
J.M.P.A. van den Reek, Lieke J. van Vugt, Martijn B. A. van Doorn, et al.
Acta Dermato Venereologica (2018) Vol. 98, Iss. 7, pp. 648-654
Open Access | Times Cited: 59
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Philip J. Mease, Iain B. McInnes
Rheumatology and Therapy (2016) Vol. 3, Iss. 1, pp. 5-29
Open Access | Times Cited: 58
Discovery of [cis-3-({(5R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist
Mitsunori Kono, Atsuko Ochida, Tsuneo Oda, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 7, pp. 2973-2988
Closed Access | Times Cited: 58
Page 1 - Next Page

Scroll to top